Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists uncover clue to leg artery disease in MicroRNA

NCT ID NCT04089943

Knowledge-focused Sponsor: University of West Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at a molecule called microRNA-210 in 230 people with peripheral artery disease (PAD), a condition where leg arteries become blocked. Researchers measured its levels and linked them to oxidative stress and walking ability. The goal was to understand how this molecule might be used as a target for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new treatments for peripheral artery disease by targeting microRNA-210 to improve walking and quality of life.
What could go wrong
This is a completed observational study, not a treatment trial. The findings may not directly lead to therapies, and further research is needed to confirm any benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

230 people

The number who actually took part.

Started

Sep 2019

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. male or female 30 years or older, 2. Infrainguinal PAD, 3. critical limb ischemia, defined as arterial insufficiency with gangrene, nonhealing ischemic ulcer, or rest pain consistent, 4. candidate for both endovascular and open infra-inguinal revascularization as judged by the vascular surgeons, 5. absence of musculoskeletal (most commonly arthritis related) or neurologic (most commonly back pain and sciatica related) symptoms, 6. willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent. Exclusion Criteria: 1. life expectancy of less than 2 years due to reasons other than PAD, 2. acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma, 3. current chemotherapy or radiation therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial occlusive diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arterial Occlusive Diseases atherosclerosis limb ischemia peripheral arterial disease peripheral vascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial occlusive diseases Atherosclerosis Peripheral arterial disease Vascular diseases, peripheral

Contacts and locations

Locations

  • Baylor Scott and White

    Temple, Texas, 76508, United States

  • UT Austing Dell Medical School

    Austin, Texas, 78712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.